非小细胞肺癌患者血清肝癌衍生生长因子、血管内皮生长因子的水平及意义

doi:10.6040/j.issn.1671-7554.1.2014.008

摘要/Abstract

摘要： 目的探讨肝癌衍生生长因子（HDGF）、血管内皮生长因子（VEGF）在非小细胞肺癌（NSCLC）患者血清中的表达及意义。方法选择非小细胞肺癌患者30例为肺癌组，良性肺部疾病患者30例为良性肺病组，健康人30例为对照组。比较各组血清HDGF、VEGF水平，分析肺癌组患者血清HDGF、VEGF水平的相关因素，对肺癌组患者血清HDGF、VEGF水平进行相关性分析。结果良性肺病组血清HDGF水平高于对照组（P<0.01），VEGF水平低于对照组（P<0.01）。肺癌组血清HDGF、VEGF水平高于对照组（P<0.01）；HDGF水平低于良性肺病组（P<0.01），VEGF水平高于良性肺病组（P<0.01）。肺癌组血清HDGF、VEGF水平与性别、年龄无统计学相关，与吸烟、病理类型、分化程度、病理分期、淋巴结转移密切相关。肺癌组患者血清HDGF、VEGF水平呈正相关（r=0.33， P<0.01）。结论血清HDGF水平与肺癌分期密切相关，血清VEGF水平、淋巴结状态与肺癌分期密切相关，二者对NSCLC患者病程的判定有一定帮助。

关键词: 血管内皮生长因子, 血清, 非小细胞肺, 癌, 肝癌衍生生长因子

Abstract: Objective To explore the expressions and significances of serum hepatic cancer-derived growth factor (HDGF) and vascular endothelial growth factor (VEGF) in patients with non-small cell lung cancer (NSCLC). Methods A total of 30 patients with NSCLC served as NSCLC group while other 30 patients with benign lung disease as benign lung disease group, and 30 healthy people as control group. Serum HDGF and VEGF levels were compared among the three groups and analyzed in NSCLC group for their relevant factors and relationship. Results Benign lung disease group was evidently higher in serum HDGF level and lower in VEGF level than control group (P<0.01), while NSCLC group was obviously higher than control group in both HDGF and VEGF levels (P<0.01). However, NSCLC group was markedly lower in HDGF level but higher in VEGF level than benign lung disease group (P<0.01). Serum HDGF and VEGF levels had no significant relationship with ages and genders in NSCLC group, but they had apparent association with smoking history, adeno-carcinoma, non- and low- differentiation, pathological stage and lymph node metastasis. Serum HDGF and VEGF levels were positively correlated(r=0.33, P<0.01). Conclusion Serum HDGF level has close association with clinical stages, and serum VEGF level is closely correlated with conditions of lymph nodes and clinical stages of lung cancers, so they are helpful in the diagnosis of NSCLC.

Key words: Hepatic cancer-derived growth factor, Serum, Vascular endothelial growth factor, Non-small cell lung cancer

中图分类号:

R734.2

袁志平, 牟华平, 陈佳莲, 邓黎. 非小细胞肺癌患者血清肝癌衍生生长因子、血管内皮生长因子的水平及意义[J]. 山东大学学报（医学版）, 2014, 52(9): 63-66.

YUAN Zhiping, MOU Huaping, CHEN Jialian, DENG Li. Expressions and significances of serum hepatic cancer-derived growth factor and vascular endothelial growth factor in patients with non-small cell lung cancer[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(9): 63-66.

参考文献

[1] 洪群英, 张勇, 白春学. 肺癌筛查和早期诊断的现状[J]. 国际呼吸杂志, 2013, 33(24):1888-1891. HONG Qunying, ZHANG Yong, BAI Chunxue. Lung cancer screening: present situation and controversy[J]. Int J Res, 2013, 33(24):1888-1891.
[2] Zhao J, Ma M Z, Ren H, et al. Anti-HDGF targets cancer and cancer stromal stem cells resistant to chemotherapy[J]. Clin Cancer Res, 2013, 19(13):3567-3576.
[3] 周世杰, 许绍发, 张海青, 等. 肝癌衍生生长因子在Ⅰ期非小细胞肺癌中的表达及其临床意义[J]. 中华肿瘤杂志, 2007, 29(12):927-930. ZHOU Shijie, XU Shaofa, ZHANG Haiqing, et al. Expression of HDGF and its implication in stage I non-small cell lung cancer[J]. Chin J Oncol, 2007, 29(12):927-930.
[4] Nakamura H, Izumoto Y, Kambe H, et al. Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein[J]. J Biol Chem, 1994, 269(40):25143-25149.
[5] Ke Y, Zhao W, Xiong J, et al. Downregulation of miR-16 promotes growth and motility by targeting HDGF in non-small cell lung cancer cells[J]. FEBS Lett, 2013, 587(18):3153-3157.
[6] Iwasaki T, Nakagawa K, Nakamura H, et al. Hepatoma-derived growth factor as a prognostic marker in complete-ly resected non-small-cell lung cancer[J]. Oncol Rep, 2005, 13(6):1075-1080.
[7] Kim J W, Koh Y, Kim D W, et al. Clinical implications of VEGF, TGF-β1, and IL-1β in patients with advanced non-small cell lung cancer[J]. Cancer Res Treat, 2013, 45(4):325-333.
[8] Zhao Y, Yu D, Wu H, et al. Anticancer activity of SA-HA, a potent histone deacetylase inhibitor,in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo[J]. Int J Oncol, 2014, 44(2):451-458.
[9] Smith N R, Baker D, Farren M, et al. Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy[J]. Clin Cancer Res, 2013, 19(24):6943-6956.
[10] 李白翎, 金磊, 钟铿, 等. 非小细胞肺癌组织Bmi-1和VEGF表达及其临床意义的研究[J]. 中华肿瘤防治杂志, 2012, 19(21):1610-1613. LI Bailin, JIN Lei, ZHONG Keng, et al. Expression and clinical significance of Bmi-1 and vascular endotheli-al growth factors in non-small cell lung cancer[J]. Chin J Cancer Prev Treat, 2012, 19(21):1610-1613.
[11] 孙洪岩, 操乐杰, 张爱梅, 等. 肺癌患者外周血循环内皮细胞和VEGF检测临床意义的探讨[J]. 中华肿瘤防治杂志, 2011, 18(13):1027-1031. SUN Hongyan, CAO Lejie, ZHANG Aimei, et al. Clinical significance of measuring peripheral circulating endothelial cells and VEGF in patients with lung cancer[J]. Chin J Cancer Prev Treat, 2011, 18(13):1027-1031.
[12] Li D, Han Z, Liu J, et al. Upregulation of nucleus HDGF predicts poor prognostic outcome in patients with penile squamous cell carcinoma bypass VEGF-A and Ki-67[J]. Med Oncol, 2013, 30(4):702.
[13] Chen S C, Kung M L, Hu T H, et al. Hepatoma-de-rived growth factor regulates breast cancer cell invasion by modulating epithelial-mesenchymal transition[J]. J Pathol, 2012, 228(2):158-169.
[14] 刘霞, 田荣华, 马桂芳. 非小细胞肺癌组织中肝癌衍生生长因子和血管内皮生长因子的表达及意义[J]. 肿瘤研究与临床, 2013, 25(9):634-636. LIU Xia, TIAN Ronghua, MA Guifang. The expression and significance of hepatocellular carcinoma (HCC) and vascular endothelial growth factor in non-small cell lung cancer tissues[J]. Cancer Res Clin, 2013, 25(9):634-636.
[15] 刘勤, 张军.G LO1蛋白在非小细胞肺癌组织中的异常表达[J]. 中国医科大学学报, 2013, 42(1):77-78. LIU Qin, ZHANG Jun. Abnormal expression of GLO1 in non-small cell lung cancer[J]. J Chin Med Univer, 2013, 42(1):77-78.

相关文章 15

[1]	王韶卿刘毅慧付婷婷成金勇刘强. 肝癌³¹磷磁共振波谱数据的分类[J]. 山东大学学报(医学版), 2209, 47(6): 42-46.
[2]	吕艳锋丁克王建新禹化龙贝绍生. 慢性肛瘘癌变诊疗分析[J]. 山东大学学报(医学版), 2209, 47(6): 55-57.
[3]	李波波李道堂刘曙光王兴武. 食管癌患者血清中DKK-1的表达[J]. 山东大学学报(医学版), 2209, 47(6): 58-61.
[4]	黄方康瑞吴春林. VEGFC、NF-κBp65及Survivin在鼻咽癌中的表达及临床意义[J]. 山东大学学报(医学版), 2209, 47(6): 83-.
[5]	张辉时庆侯怀水李栋. 人脐带间充质干细胞的无动物血清培养及向肝细胞诱导分化[J]. 山东大学学报(医学版), 2209, 47(6): 88-.
[6]	李宁张征张宏群高希宝. 济南居民膳食硒摄入量与血清硒参考值调查[J]. 山东大学学报(医学版), 2209, 47(6): 121-122.
[7]	张媛李英敏冯月秋常彩云潘华伟王束玫. 血清脂联素水平与肥胖、胰岛素抵抗的关系探讨[J]. 山东大学学报(医学版), 2209, 47(6): 124-.
[8]	于德新蔡跃红马祥兴张晓明李传福. 肝细胞癌血管生成及其成熟度的临床意义[J]. 山东大学学报(医学版), 2209, 47(6): 51-54.
[9]	李儆修,李忠慧,李闻天,王宇男,宋泽辉,庄大勇,贺青卿,周鹏. 光电检测仪在甲状腺癌术中的初步应用[J]. 山东大学学报 (医学版), 2026, 64(4): 31-37.
[10]	黄佩文, 王旭东. 治疗非小细胞肺癌新药:靶向c-Met蛋白的抗体药物偶联物Telisotuzumab Vedotin[J]. 山东大学学报 (医学版), 2026, 64(3): 124-130.
[11]	殷悦,莫振飞,吴培昕,刘金霞,魏元辉,任佳博,李春笋. GPX1基因在肺癌中的表达特征及其对肺腺癌细胞增殖、迁移、侵袭、凋亡的影响[J]. 山东大学学报 (医学版), 2026, 64(1): 65-73.
[12]	古春青,郭睿思,周勤勤,刘恒辉,巴婉玉,孙士玲,王冰,郑玉玲,吴宿慧. 基于网络药理学和动物实验探讨酸枣仁-远志药对治疗乳腺癌相关性失眠的作用机制[J]. 山东大学学报 (医学版), 2026, 64(1): 99-108.
[13]	李晶,鞠苇杭,刘珂. 泛癌细胞类型特异性基因共表达模式[J]. 山东大学学报 (医学版), 2025, 63(9): 31-39.
[14]	李雪凯,孙淋涵,刘端瑞,倪阳. 乳酸化修饰在肿瘤炎癌进程中的功能与机制研究进展[J]. 山东大学学报 (医学版), 2025, 63(9): 65-76.
[15]	李梓绮,魏闫若雪,刘晓晗,刘春铖,赵然,刘玉昆. 长链非编码RNA HEATR3反义RNA 1参与结直肠癌发生发展的功能及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(9): 108-115.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed